Navigation Links
Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
Date:1/31/2008

nt assets under marketable securities on the company's balance sheet. Given the failed auctions, the company's ARS are illiquid until there is a successful auction for them. Accordingly, the entire amount of such remaining ARS has been reclassified from current to non-current assets on the company's balance sheet.

If uncertainties in the credit and capital markets continue, these markets deteriorate further or the company experiences any additional ratings downgrades on any investments in its portfolio (including on ARS), the company may incur additional impairments to its investment portfolio, which could negatively affect the company's financial condition, cash flow and reported earnings. The company believes that based on the company's current cash, cash equivalents and marketable securities balances of $2.2 billion at December 31, 2007 and expected operating cash flows, the current lack of liquidity in the credit and capital markets will not have a material impact on the company's liquidity, cash flow, financial flexibility or its ability to fund its operations, including the dividend.

For information on specified items, see Appendix 2. Details reconciling these non-GAAP amounts with GAAP amounts including specified items are provided in Appendix 1 attached and in supplemental materials available on the company's website.

PHARMACEUTICALS

Worldwide pharmaceutical sales increased 39% to $4.4 billion in the fourth quarter of 2007, including a 5% favorable foreign exchange impact, compared to the same period in 2006.

U.S. pharmaceutical sales increased 65% to $2.5 billion in the fourth quarter of 2007 compared to the same period in 2006, primarily due to increased PLAVIX(R) sales, as well as the continued growth of ABILIFY(R), REYATAZ(R), the SUSTIVA(R) Franchise and ERBITUX(R), and sales of newer products ORENCIA(R), BARACLUDE(R), SPRYCEL(TM) and IXEMPRA(TM).

International pharmaceutical sales increased 16%, including a 10%
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine news :

1. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
2. Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors
3. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
4. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
5. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
6. Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
7. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
8. Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
9. Bristol-Myers Squibb Announces Dividend
10. P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create Stand-Alone Coffee Company
11. First Pharmaceutical Company Comes to Hoboken, NJ: Swiss-Based Octapharma to Move U.S. Headquarters to SJP Properties Waterfront Corporate Center II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... (PRWEB) May 23, 2013 Teen birth rates ... according to new data released today by the ... the teen birth rate dropped at least 15% in 48 ... , There were also dramatic declines among all racial/ethnic groups ... ,     Birth rates declined 40% or more for Hispanic teens ...
(Date:5/23/2013)... May 23, 2013 To better ... DORMA company, is pleased to announce the release ... for its pacesetting space division products. Provided by ... wallcoverings, the new patterns and colors represent a ... Through meetings with a team of Koroseal experts, ...
(Date:5/23/2013)... can cause rapidly progressing, life threatening meningitis and meningococcal ... have not known how it attaches to the human ... attaches to the airway to colonise", People can be ... while some people progress to invasive disease. To ... how the bacterium colonises the airway. Now that the ...
(Date:5/23/2013)... According to a new market report ... Subscriber Data Management (SDM); Telecom Application Server; Service Creation ... – 2018)", published by MarketsandMarkets, the SDP Market is ... CAGR of 9.15% from 2013 to 2018. , Browse:, ... 84 Figures , 189 Pages ...
(Date:5/23/2013)... May 23, 2013 Verndale, an ... the launch of Current Digital, a business dedicated ... and digital marketing needs. Companies now view content ... business necessity. This can often leave agencies placed ... on preselected software platforms that they may not ...
Breaking Medicine News(10 mins):Health News:Modernfold Debuts New Colors and Patterns for Space Division Products 2Health News:New discovery in fight against deadly meningococcal disease 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 2Health News:Verndale Launches Current Digital, a Technology Partner for Ad and Creative Agencies 3
... being punched by electrical pulses could give better delivery ... treatments //including cancer therapy and gene therapy are limited ... cell membranes. Researchers in San Diego, California, have been ... which involves punching tiny holes into cell membranes using ...
... visions of adult stem cells as a less honestly questionable ... ability to sprout different cell types has spawned debate between ... who say it has life-saving potential. The new findings challenge ... directly produce cell types of other tissues and organs.// It ...
... Food and Drug Administration recommended that three popular allergy drugs ... FDA does not have to follow the advice of its ... for making a decision. // ,"Drugs are prescription ... good and harm. Claritin, Allegra and Zyrtec have almost no ...
... Tea derived from the plants Camellia sinensis contains polyphenols ... flavanols, which gives the tea its antioxidant properties. Polyphenols ... oxidative stress. , ... occur naturally in the body and an increased amount ...
... to a new study shows that women with ... 'good' cholesterol when they take oestrogen.// Previous research suggests ... heart disease. Now doctors at Forest University have discovered ... profile responds to HRT. ,An analysis of over ...
... in University of Texas, a novel blood test can detect ... to predict who might get Alzheimer's disease.Researchers at the School ... a similar blood test would work in people, but the ... ruins brain cells and is the cause of Alzheimer's. Some ...
Cached Medicine News:Health News:A question on study of Adult Stem Cell 2Health News:A question on study of Adult Stem Cell 3Health News:Blood test may aid foretell Alzheimer's 2
(Date:5/23/2013)...  Omeros Corporation (NASDAQ: OMER ) ... (IND) to evaluate OMS824 in Huntington,s disease has ... Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), ... linked to a wide range of diseases that ... has shown promising results in animal models directly ...
(Date:5/23/2013)... ATLANTA , May 23, 2013  Inhibikase ... treatments, announced today that it will present new ... at an industry conference sponsored by the PML ... Biogen Idec).  JC polyomavirus (JCV) is the causative ... host-directed tyrosine kinase inhibitor in an extended release ...
(Date:5/23/2013)... , May 23, 2013 ... MKT: NSPR), the leader in embolic protection stents, ... (MGuard for Acute ST Elevation Reperfusion) trial demonstrating ... bare metal and drug eluting stents in all-cause ... patients.  Results from the trial were presented at ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: